Navigation Links
Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting
Date:12/6/2008

ickle cell disease.

Recombinant Human Erythropoiesis Stimulating Agents in Cancer Patients: IndividualPatient Data Meta-Analysis on Behalf of the EPO IPD Meta-Analysis Collaborative Group [LBA-6]

Julia Bohlius, M.D., MScPH, University of Bern, Bern, Switzerland

*Abstract LBA-6 is being presented on Saturday, December 6, at 2:00 p.m. at the ASH press conference on treatment advances in leukemia and lymphoma. The embargo for this abstract will break at that time.

Results of this first large-scale study examining how survival rates are affected by the use of erythropoiesis-stimulating agents (ESAs) for the treatment of anemia in patients with cancer showed that ESAs increased on-study mortality and worsened overall survival, confirming previous studies that have suggested that ESAs may negatively affect the overall health of these patients.

In order to assess the effect of ESAs on mortality, a meta-analysis was conducted of 13,933 patients with cancer enrolled in 53 randomized, controlled clinical trials comparing epoetin alfa, epoetin beta, and darbepoetin alfa plus red blood cell transfusions versus red blood cell transfusions alone for the prevention or treatment of anemia during or after receiving anticancer therapy. Thirty-eight of these trials, which included 10,441 patients, used chemotherapy as the anticancer regimen.

The primary endpoints of the study were on-study mortality and overall survival in patients with cancer receiving chemotherapy, including all studies where more than 70 percent of patients enrolled received chemotherapy, and all patients with cancer regardless of the type of anticancer therapy. On-study mortality was defined as death from any cause between the date of being randomized in the clinical trial and 28 days following the end of the treatment phase of the study. Overall
'/>"/>

SOURCE American Society of Hematology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
2. New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nations Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. University of Kansas Medical Center to Deploy Velos eResearch System-Wide
5. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
6. Dominos Pizza Pledges Support to the Fifth Annual St. Jude Childrens Research Hospital(R) Thanks and Giving(R) Campaign
7. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
8. Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
9. Sarah Cannon Research Institute Selects OmniComm Systems Electronic Data Capture Solution, TrialMaster(TM), for Clinical Trials Management
10. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
11. SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Sept. 23, 2014   LabStyle Innovations Corp ... Management Solution, today announced that it has closed ... shares of preferred stock and warrants.  No placement ... offering expenses, LabStyle expects to secure net proceeds ... LabStyle intends to use the net ...
(Date:9/23/2014)... , September 23, 2014 ... améliorée lors d,une série de démonstrations personnelles   ... dans le domaine de l,analyse de la ... au stand n° 1035 lors de la réunion ... San Diego , en Californie. FDNA ...
(Date:9/23/2014)... , Sept. 23, 2014 Report Details ... showing you trends, R&D and predicted revenues Do ... inhibitors? Now get the latest analysis for those ... results, opportunities and revenue forecasts. Visiongain,s new ... protein kinase inhibition and related technology. There avoid ...
Breaking Medicine Technology:LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 2LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 3LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 4LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 5FDNA exposera sa solution Face2Gene intégrée en ligne avec London Medical Databases (LMD) à l'ASHG 2014 2FDNA exposera sa solution Face2Gene intégrée en ligne avec London Medical Databases (LMD) à l'ASHG 2014 3Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 2Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 3Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 4Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 5
... 22, 2011 /PRNewswire-Asia/ -- China Health Resource, Inc. (OTCBB: ... (TCM) products, announced robust record breaking quarterly earnings for ... and $1.8 million in net income, a 219% increase ... the third quarter of 2010. This translates to earnings ...
... HILL, N.C., Nov. 21, 2011  In today,s payer-driven market, ... of a new pharmaceutical product. However, sustaining commercial success ... processes that will increase market share after the product ... of practices to manage the challenges of the pull-through ...
Cached Medicine Technology:China Health Resource Announces Record Breaking 3rd Quarter 2011 Financial Results 2China Health Resource Announces Record Breaking 3rd Quarter 2011 Financial Results 3Managed Care Pull-Through Programs Target Physicians, Boost Market Share 2
(Date:9/23/2014)... (PRWEB) September 23, 2014 "The primary purpose ... control," said an inventor from Sacramento, Ca.. "Call lights are ... or left hanging on the IV pole out of the ... the nurse call device whenever they need it, I created ... effectively position the nurse call device within easy reach. The ...
(Date:9/23/2014)... Davis, and Academia Sinica, the preeminent academic institution ... into a collaborative agreement to develop a unique ... research with opportunities to translate innovative technologies and ... agreement was signed Sept.12 in Taipei by Harris ... and President Chi-Huey Wong of Academia Sinica. The ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 AttorneyOne.com, a ... all the latest information from the FDA on ... 5, that its Private Label Jalapeno Bagels are recalled ... stones. Publix Jalapeno Bagels were sold in ... department. , Taking into consideration the latest developments, ...
(Date:9/23/2014)... Kathleen Doheny HealthDay Reporter ... at very low birth weights, breast milk is more likely ... infection known as cytomegalovirus (CMV), a new study finds. ... infants -- all of whom weighed 3.3 pounds or less ... of CMV infection, to see whether breast milk or transfusions ...
(Date:9/23/2014)... 2014 (HealthDay News) -- Both drinking and getting drunk ... alcohol abuse by high school students, a new study ... high school students who drink, could help expand alcohol-prevention ... drink, to stop them from becoming binge drinkers, the ... of first alcohol use and progression to first heavy ...
Breaking Medicine News(10 mins):Health News:Academia Sinica, UC Davis sign agreement on exchanges and tech transfer 2Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 3Health News:Younger Age at First Drink, Higher Odds for Problem Drinking: Study 2Health News:Younger Age at First Drink, Higher Odds for Problem Drinking: Study 3
... Reactors Could Solve the Isotope Crisis within 24 months ... Nordion, a leading provider of medical isotopes and radiopharmaceuticals, ... Expert Review Panel on Medical Isotope and Technetium-99m (Tc-99m) ... to the shortage of medical radioisotopes is the completion ...
... male and seven female) with hepatic angiomyolipoma, with a ... Of these patients, dynamic contrast CT showed hepatic angiomyolipoma ... of a capsule, and prominent central vessels in six ... without a fat component in four cases with tuberous ...
... , DENVER July 30 Air Methods Corporation ... quarter ended June 30, 2009 after the close of the market on ... for Thursday, August 6, 2009 at 4:15 p.m. Eastern to discuss these ... the call by dialing (877) 883-0656 (domestic) or (706) 643-8826 (international) or ...
... , PLEASANTON, Calif., July 30 TriReme ... second product, a novel coronary dilatation catheter, designed to improve ... near side branches. The product will be marketed under the ... a first-in-class balloon dilatation catheter with a torquable shaft and ...
... centers didn,t increase weight, study found , THURSDAY, July 30 ... else,s home, they,re more likely to be heavier than average ... researchers report in the August issue of Pediatrics ... for in someone else,s home, rather than in their own ...
... WILMINGTON, Del., July 30 AstraZeneca (NYSE: ... a New Drug Application to the U.S. Food and Drug ... European Medicines Agency (EMEA) for an investigational drug, vandetanib 100 ... of advanced non-small cell lung cancer in patients previously treated ...
Cached Medicine News:Health News:MDS Nordion Submits Expression of Interest Proposal to Government of Canada on Medical Isotope and Generator Production 2Health News:MDS Nordion Submits Expression of Interest Proposal to Government of Canada on Medical Isotope and Generator Production 3Health News:TriReme Medical, Inc. Receives CE Marking for Glider(TM) PTCA Dilatation Catheter 2Health News:Infants Cared for in Another Home Become Heavier Toddlers 2Health News:Infants Cared for in Another Home Become Heavier Toddlers 3Health News:AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer 2Health News:AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer 3Health News:AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer 4
... ALLEGRO Topolyzer and T-CAT have been optimized ... vision correction and to interact in perfect ... systems. All necessary treatment and patient parameters ... the ALLEGRETTO WAVE laser systems via diskette, ...
RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% is the first and only therapy for patients with keratoconjunctivitis sicca (Dry Eye Disease) whose tear production is presumed to be supressed d...
ZYMAR™ ophthalmic solution is an anti-infective prescription eye drop that your doctor may instruct you to use if you have an eye infection caused by bacteria. Bacterial conjunctivitis is the e...
... P.M.® lets you sleep on ... in the morning awake with ... ready to take on the ... comfort and protection, this preservative-free ...
Medicine Products: